Patents Assigned to Mochida Pharmaceuticals Co., Ltd.
  • Factor IXa inhibitors
    Patent number: 9914727
    Abstract: The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 13, 2018
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, John Qiang Tan, Ting Zhang, James Balkovec, William John Greenlee, Liangqin Guo, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, Tomokazu Hirabayashi, Mika Sekioka
  • Pyrazole derivative manufacturing method
    Patent number: 9902723
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: February 27, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • Compositions and methods for treating non-alcoholic steatohepatitis
    Patent number: 9889108
    Abstract: The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 13, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
  • Factor IXa Inhibitors
    Publication number: 20180030036
    Abstract: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
    Type: Application
    Filed: December 7, 2015
    Publication date: February 1, 2018
    Applicants: MERCK SHARP & DOHME CORP., MOCHIDA PHARMACEUTICAL CO., LTD
    Inventors: Ting Zhang, Yi-Heng Chen, Liangqin Guo, Alan Hruza, Tianying Jian, Bing Li, Dongfang Meng, Dann L. Parker, Edward C. Sherer, Harold B. Wood, Isao Sakurada
  • Pyrazole derivative manufacturing method
    Patent number: 9879009
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 30, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • OMEGA-3 FATTY ACID SELF-EMULSIFYING COMPOSITION
    Publication number: 20180015038
    Abstract: A pharmaceutical composition comprising, in relation to 100% by weight of a total amount of a self-emulsifying composition, 70 to 90% by weight of eicosapentaenoic acid ethyl ester as a first medicinal component, 0.5 to 6% by weight of water, 1 to 29% by weight of polyoxyethylene sorbitan fatty acid ester (optionally further comprising polyoxyethylene castor oil) as an emulsifier, 1 to 25 parts by weight of lecithin in relation to 100 parts by weight of the eicosapentaenoic acid ethyl ester, and pitavastatin, rosuvastatin, or a salt thereof as a second medicinal component. The composition is excellent in any one of self-emulsifying property, dispersibility of the composition, emulsion stability, absorbability, and storage stability of the medicinal components and a preparation.
    Type: Application
    Filed: January 20, 2016
    Publication date: January 18, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA, Daichi TANAKA
  • SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID
    Publication number: 20170368184
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Application
    Filed: January 21, 2015
    Publication date: December 28, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
  • SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID
    Publication number: 20170348268
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Application
    Filed: August 23, 2017
    Publication date: December 7, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeru KIMURA, Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
  • SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID
    Publication number: 20170348273
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Application
    Filed: January 21, 2016
    Publication date: December 7, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA, Daichi TANAKA
  • Method for regenerating cartilage comprising applying a monovalent metal salt of alginic acid and SDF-1
    Patent number: 9821027
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: November 21, 2017
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Atsushi Sukegawa, Akio Minami, Nobuo Ohzawa
  • Factor IXa inhibitors
    Patent number: 9808445
    Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 7, 2017
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Isao Sakurada, Tomokazu Hirabayashi, Yoshitaka Maeda, Hiroshi Nagasue, Takashi Mizuno, Jiayi Xu, Ting Zhang, Cameron Smith, Dann Parker
  • Self-emulsifying composition of ?3 fatty acid
    Patent number: 9801843
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: October 31, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeru Kimura, Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata
  • Easily dosable solid preparation
    Patent number: 9789068
    Abstract: It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: October 17, 2017
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Yumio Kudou, Kuniomi Warabino, Hiromitsu Ito
  • Pyrazole derivative
    Patent number: 9777000
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 3, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Kouki Ogawa
  • CARDIOVASCULAR DISEASE PRIMARY PREVENTION AGENT FOR PATIENTS HAVING HIGH BLOOD LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN
    Publication number: 20170273929
    Abstract: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
    Type: Application
    Filed: June 9, 2017
    Publication date: September 28, 2017
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yutaka KIYOHARA, Toshiharu NINOMIYA, Takashi YANO
  • COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT
    Publication number: 20170273928
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • PYRAZOLE DERIVATIVE MANUFACTURING METHOD
    Publication number: 20170217958
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • PYRAZOLE DERIVATIVE MANUFACTURING METHOD
    Publication number: 20170210740
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
    Type: Application
    Filed: July 29, 2015
    Publication date: July 27, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Composition for preventing the occurrence of cardiovascular event in multiple risk patient
    Patent number: 9700537
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: July 11, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity C-reactive protein
    Patent number: 9700538
    Abstract: The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: July 11, 2017
    Assignees: MOCHIDA PHARMACEUTICAL CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yutaka Kiyohara, Toshiharu Ninomiya, Takashi Yano